Jaydip Ghadage's Blog

Catheter Related Bloodstream Infection (CRBSI) Market Proposal, Demand And Trade Analysis 2023 to 2033

Jaydip Ghadage's photo
Jaydip Ghadage
·

3 min read

The Catheter Related Bloodstream Infection (CRBSI) Market is anticipated to reach US$ 44.67 billion in 2023 and US$ 80 billion by 2023 to 2033 at a CAGR of 6%. The rise in the market for catheter-related bloodstream infections can be linked to the rise in the number of persons who experience urine infections. The market for catheter-related bloodstream infections increased historically at a CAGR of 4.5% from 2017 to 2022.

An increasing number of surgeries due to a rise in the number of chronic ailments such as diabetes, cardiovascular disorders, urological disorders, end-stage renal diseases, and other chronic conditions is expected to increase the adoption rate of catheters. This, in tun, is expected to increase the chances of patients suffering from catheter-related bloodstream infection market.

To learn more about this report: https://www.futuremarketinsights.com/reports/catheter-related-bloodstream-infection-crbsi-market

Furthermore, technological advancements play crucial role in fueling the market growth. For instance, miniaturized catheters and introduction of antimicrobial catheters are expected to reduce catheter-associated infections Although major players are innovating, launching and introducing safer catheters, the limited expansion of the same is contributing to the market for catheter-related bloodstream infusions.

Key Takeaways from the Market Study

  • By distribution channel, hospital pharmacies are expected to possess 40% market share for catheter-related bloodstream infections market in 2023.

  • By drug class, antimicrobial catheters are expected to possess 35% market share for catheter-related bloodstream infections in 2023.

  • North America is expected to possess 35% market share for catheter-related bloodstream infection market in 2023.

  • Asia Pacific is expected to possess 30% market share for catheter-related bloodstream infection market in 2023.

“Rise in prevalence of diseases that require catheter are increasing the number of patients suffering from catheter-related bloodstream infections. This, in turn, is supporting the growth of the market.” states a FMI analyst

Competitive Landscape

Key players in the catheter-related bloodstream infection are Xellia Pharmaceuticals Ltd, Pfizer, Glenmark Pharmaceuticals Ltd, Fresenius Medical Care, CorMedix, TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca Pharma India Ltd, Merck Sharp & Dohme Corp

  • In August 2021, Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.

  • In February 2020, CorMedix, Inc. announced that Neutrolin received grant from the U.S. Food and Drug Administration for the prevention of catheter-related bloodstream infections (CRBSIs) in hemodialysis patients.

Central line-associated bloodstream infection (CLABSI) is an infection that occurs when bacteria or other microorganisms enter the bloodstream through a catheter. Catheters are medical devices that are inserted into the body to deliver fluids, medications, or nutrition. They are commonly used in hospitals, long-term care facilities, and in the home for patients who require ongoing medical treatment.

Key Companies Profiled:

  • Xellia Pharmaceuticals Ltd.

  • Pfizer

  • Glenmark Pharmaceuticals Ltd.

  • Fresenius Medical Care

  • CorMedix

  • TauroPhar GmbH

  • Geistlich Pharma

  • Citus Pharmaceuticals

  • AstraZeneca Pharma India Ltd.

  • Merck Sharp & Dohme Corp

Key Segments Profiled in the Catheter-Related Bloodstream Infection Market Industry Survey

Drug Class:

  • Non-antibiotic

  • Anti-infective

  • Antimicrobial

Pathogens:

  • Contaminated Catheter Hub

  • Contaminated Infusate

  • Skin Insertion

  • Hematogenous

Source of Infection:

  • Aureus

  • Aeruginsa

  • CONS

  • Baumanii

  • Coli

  • Pnemoniae

  • Candida sp

Route of Administration:

  • Oral

  • Intravenous

Distribution Channel:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

Catheter Related Bloodstream Infection (CRBSI) Market